Guang Han

机构：Hubei Cancer Hospital, Huazhong University of Science and Technology

发表论文 7 篇 · 总被引 186 次 · h-index 3

代表论文

• Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial (2024 · The Lancet Respiratory Medicine · 被引 122)
• Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial (2024 · Cancer Cell · 被引 59)
• Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial. (2024 · Journal of Clinical Oncology · 被引 3)
• High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis. (2024 · Journal of Clinical Oncology · 被引 1)
• Molecular cloning and tissue expression patterns of a small conductance calcium-activated potassium channel gene in turbot (Scophthalmus maximus L.) (2009 · Fish & Shellfish Immunology · 被引 1)
• MOESM1 of Characterization and selective incorporation of small non-coding RNAs in non-small cell lung cancer extracellular vesicles (2018 · Figshare)